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Chronic opioid pretreatment potentiates the sensitization of
fear learning by trauma
Zachary T. Pennington1,2,3, Jeremy M. Trott 1,2, Abha K. Rajbhandari1,2, Kevin Li 1, Wendy M. Walwyn 4,5, Christopher J. Evans4,5 and
Michael S. Fanselow1,2,4
Despite the large comorbidity between PTSD and opioid use disorders, as well as the common treatment of physical injuries
resulting from trauma with opioids, the ability of opioid treatments to subsequently modify PTSD-related behavior has not been
well studied. Using the stress-enhanced fear learning (SEFL) model for PTSD, we characterized the impact of chronic opioid
regimens on the sensitization of fear learning seen following traumatic stress in mice. We demonstrate for the first time that chronic
opioid pretreatment is able to robustly augment associative fear learning. Highlighting aversive learning as the cognitive process
mediating this behavioral outcome, these changes were observed after a considerable period of drug cessation, generalized to
learning about multiple aversive stimuli, were not due to changes in stimulus sensitivity or basal anxiety, and correlated with a
marker of synaptic plasticity within the basolateral amygdala. Additionally, these changes were not observed when opioids were
given after the traumatic event. Moreover, we found that neither reducing the frequency of opioid administration nor bidirectional
manipulation of acute withdrawal impacted the subsequent enhancement in fear learning seen. Given the fundamental role of
associative fear learning in the generation and progression of PTSD, these findings are of direct translational relevance to the
comorbidity between opioid dependence and PTSD, and they are also pertinent to the use of opioids for treating pain resulting
from traumas involving physical injuries.
Neuropsychopharmacology (2020) 45:482–490; https://doi.org/10.1038/s41386-019-0559-5
INTRODUCTION
Post-traumatic stress disorder (PTSD) is highly comorbid with
substance use disorder (SUD), with nearly 40% of individuals with
PTSD also having SUD [1–6]. Understanding this comorbidity
could shed fundamental mechanistic light on disease origins.
Traditional models of PTSD–SUD comorbidity propose that SUD
emerges as a consequence of PTSD. In support of this, longitudinal
studies confirm that PTSD increases risk for SUD [4] and animal
studies have shown that stressors are able to potently drive drug-
seeking [7]. Nevertheless, this does not preclude the possibility
that substance use is also able to influence the development of
PTSD. The potential ability of opioid use to augment PTSD is
particularly relevant to PTSD–SUD comorbidity. Large-scale
epidemiological studies indicate that nearly 35% of individuals
with an opioid use disorder have comorbid PTSD [3, 8, 9], among
the highest of any SUD [3]. This raises the concern that opioid use
could directly facilitate PTSD development. Moreover, because
individuals that experience trauma are commonly prescribed
opioids, the ability of these medications to alter the progression of
PTSD is an important factor to consider. Here, we assessed the
impact of chronic opioid regimens on the subsequent develop-
ment of PTSD-like behaviors using the stress-enhanced fear
learning (SEFL) model. We have previously demonstrated that
SEFL captures several lasting anxiogenic changes in response to
traumatic stress, including augmented fear learning, increased
anxiety and startle responses, and altered glucocorticoid cycling
[10–14]. Moreover, this model has recently been used to
characterize long-lasting trauma-induced changes in drug seeking
[15], making it optimal to study bidirectional interactions between
trauma and drug use. We found that opioid exposure was able to
markedly potentiate the ability of trauma to augment fear
learning, and that this persisted at least a week after opioid
cessation, a time in which weight changes, anxiety-like differences
and differences in shock reactivity, were not apparent. Moreover,
this change appears to be a direct ramification of opioid exposure
rather than acute withdrawal.
METHODS AND MATERIALS
Animals
C57 BL/6J mice, 2–3 months of age, were obtained from Jackson
Laboratories and housed individually for 2–4 weeks before testing.
After initially showing that the effects of morphine were the same
in both sexes, the remaining experiments were performed in
males. The Chancellor’s Animal Research Committee at UCLA
approved all experiments.
Drug treatments
Chronic morphine injections. Animals were administered a
common escalating regimen of twice-daily morphine sulfate
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(National Institutes of Drug Abuse; Bethesda MD), or an equivalent
volume of saline, over the course of eight consecutive days. The
dose of each injection on successive days was as follows: Day 1=
10mg/kg; Day 2= 20mg/kg; Day 3= 30mg/kg; Day 4= 40mg/
kg; Days 5–8= 50mg/kg. Injections were subcutaneously admi-
nistered daily between 8–10 a.m. and 5–7 p.m at a volume of 10
ml/kg. This dosing regimen was intended to mimic a pattern of
escalating and cyclical systemic dosing. When the rate of
morphine injections was varied (1× vs. 2× daily) the number of
injections remained constant (i.e. 16 injections were administered
over 8 or 16 days) so that cumulative morphine exposure
remained constant.
Morphine pellet implantation and repeated naltrexone-precipitated
withdrawal. Morphine pellets containing 8.3 mg of morphine,
wrapped in sterilized nylon, or placebo pellets, were subcuta-
neously implanted below the neck to provide a continuous
supply of morphine. Pellets containing 25 mg morphine were
obtained from NIDA and cut down to size and placebo pellets
were treated similarly. In order to produce cycling of morphine
withdrawal, mice were treated with naltrexone twice-daily (0.25
mg/kg, i.p.; mornings/evenings), for 7 days, beginning the day
after pellet implantation. Withdrawal was assessed in the
morning of days 1, 3, 5, and 7, post-implant. To do so, animals
were placed in a translucent plexiglass cylinder (15.24 cm wide
by 38.1 cm tall) for 15 min immediately after saline/naltrexone
injection. The plexiglass cylinder was set atop a piece of clean
absorbent cloth that was weighed before/after the session to
assess excretion. Additionally, the number of jumps observed in
the final 10 min of each session was counted.
Behavioral testing
SEFL procedure. The SEFL procedure, which captures the ability
of trauma to sensitize fear learning [13, 16], took place across
4 days. Prior to this, all animals were habituated to handling for
3 days, ~60 s/day, and were also habituated to transport from
the vivarium to the laboratory for 2 days, 15 min/day. On the first
day, animals experienced the traumatic stressor, consisting of
10, 1 mA, 1 s shocks, pseudo-randomly distributed over the
course of an hour in a distinctly configured conditioning
chamber/context. Non-trauma animals were placed in the
context for an equivalent amount of time. Shock reactivity, a
measure of nociception, was assessed by examining average
motion during shock periods, and freezing throughout trauma
was assessed during 30 s intervals, beginning 30 s after each
shock. On the second day, animals were re-exposed to the
context of the traumatic stressor for 8 min to assess their
memory of the traumatic event. On the third day, animals were
exposed to a mild stressor in a novel environment. After 3 min
exploring the novel chamber/context, animals were given a 0.5
mA, 2 s, shock. They were taken out of the chamber 2 min later.
On the fourth day, animals were placed back in the context of
the mild stressor for 8 min. Detailed information on shock
equipment can be found in the Supplemental Methods. Notably,
although shock was used here for the mild stressor, we have also
found SEFL using a loud auditory startle stimulus [17],
demonstrating that this phenomenon is not specific to the
aversive stimulus employed. An extensive demonstration that
SEFL is a phenomenon of enhanced learning can also be found
in Rau et al. [13].
Additional details regarding the method of assessing shock
reactivity and for elevated plus maze (EPM) testing can be found
in the Supplemental Methods.
Tissue collection, immunohistochemistry, and cell counts
Detailed immunohistochemical protocols and image analysis can
be found in the Supplemental Methods.
Statistical analysis
Data were analyzed using the general linear model. Detailed
information on statistical procedures can be found in the Supple-
mental Methods.
RESULTS
Chronic opioid pretreatment potentiates SEFL
The impact of chronic opioid exposure on fear learning was first
assessed using the SEFL model for PTSD, which captures the
sensitization of fear learning observed following traumatic
experience (Fig. 1a), in addition to several other phenotypes
relevant to PTSD [13, 14, 16]. Because prior trauma is a major
predictor of who will develop PTSD in response to a subsequent
traumatic event [1, 18] this phenomenon is highly relevant to
understanding PTSD development.
Animals were treated across 8 days with twice-daily escalating
doses of morphine (10–50mg/kg), or saline, and were then given
a week of drug cessation prior to being behaviorally tested using
the SEFL procedure (Fig. 1a). Notably, by the time of behavioral
testing, morphine-treated animals had recovered from the large
morphine-induced weight loss observed (Fig. 1b. Morphine effect
on Day 8: F1,89= 321, p < 0.001; morphine effect on Day 15: F1,89=
0.29, p= 0.59), suggesting that they were beyond the period of
acute withdrawal.
During the initial trauma, animals received 10 footshocks across
the course of an hour. We have called this the trauma because this
acute stressor is able to produce a lasting sensitization of fear and
anxiety-like behaviors [13, 16]. Importantly, throughout the
trauma, morphine-treated animals did not show altered shock
reactivity (F1,41= 0.22, p= 0.65; data not shown) nor did they
freeze more than saline-treated animals after each shock (Fig. 1c.
Effect of morphine in trauma groups: F1,41= 2.86, p= 0.1;
morphine × trial interaction: F9,369= 0.57, p= 0.75). Moreover,
both groups reached an equivalent high level of freezing when
they were returned to the trauma environment the next day
for the trauma test (Fig. 1c. Effect of morphine in trauma groups:
F1,41= 0.11, p= 0.74). Thus, the initial response to trauma
appeared to be unaltered by morphine pre-exposure.
Animals were next placed into a novel environment and given
a single mild footshock (0.5 mA, 2 s). When first placed in this
environment (i.e., prior to shock), traumatized animals did not
display generalized fear relative to animals that had not
experienced the trauma (indicated by the amount of freezing),
and morphine- and saline-treated animals did not differ (effect
of morphine: F1,85= 1.7, p= 0.2; morphine × trauma interaction:
F1,85= 0.25, p= 0.62; mean baseline freezing in traumatized
animals= 0.8%. Data not shown). Furthermore, when given the
mild stressor, morphine- and saline-treated animals did not
differ in their motor response to this stimulus (effect of
morphine: F1,85 < 0.01, p= 0.97; morphine × trauma interaction:
F1,85= 0.01, p= 0.9. Data not shown). However, when returned
to this environment the next day, morphine-treated animals
displayed a profound sensitization of SEFL: animals that
experienced the trauma froze more in the environment that
had been paired with the mild stressor (Fig. 1d. Effect of trauma:
F1,85= 22.73, p < 0.001), and morphine-treated animals dis-
played this enhancement following trauma to a much greater
degree than saline-treated animals (Fig. 1d. Morphine × trauma
interaction: F1,85= 8.61, p < 0.01). Although morphine increased
freezing among animals that had received the trauma (F1,41=
12.78, p < 0.001), morphine-treated animals that had not
experienced the trauma did not display heightened fear
levels relative to saline-treated animals (F1,44= 0.42, p= 0.52).
Notably, both males and females showed this effect to a similar
degree (Fig. S1), supporting the robust nature of this
phenomenon.
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Potentiation of SEFL by chronic opioid pretreatment is not due to
changes in stimulus sensitivity or anxiety
In order to parse whether enhancements in fear were a
consequence of altered learning processes, or some other factor
influencing the expression of fear, we assessed the impact of
morphine exposure on a measure of general anxiety as well as
shock reactivity (Fig. 2a–c). We found that the morphine regimen
previously used failed to alter anxiety-like behavior in the EPM at a
time equivalent to when trauma was given (Fig. 2b. Percent time
in open arms: t22= 1.23, p= 0.23; open arm entries: t22= 1.19,
p= 0.25). Additionally, although shock reactivity increased with
shock intensity, prior morphine treatment did not influence shock
reactivity across a wide range of shock amplitudes (Fig. 2c. Effect
of intensity: F8,176= 22.81, p < 0.001; effect of morphine: F1,22=
0.84, p= 0.37; morphine × intensity interaction: F8,176= 0.68, p=
0.61).
Demonstrating that morphine’s impact on fear learning
generalized to other aversive stimuli, morphine-treated animals
also showed heightened freezing after exposing them to auditory
startle stimuli (Fig. 2d–f). A subset of animals which received
morphine/saline and were fear conditioned with a single 2 s, 0.5
mA shock, were subsequently exposed to a series of auditory
startle stimuli (2 s, 115 db, white noise, each separated by 1min) in
novel environment, and were placed back in the startle-paired
environment the next day (Fig. 2d). Morphine-treated animals did
not differ from controls with respect to baseline motion (Fig. 2e.
t25= 0.46, p= 0.65) or startle induced increases in motion (Fig. 2e.
t25= 0.19, p= 0.85). Moreover, morphine-treated animals did not
differ with respect to baseline freezing when initially placed in the
startle-paired environment (Fig. 2f. t25= 0.11, p= 0.91). However,
morphine-treated animals did show increased post-startle freezing
(Fig. 2f. F1,25= 5.17, p= 0.03). Importantly, this within-session
freezing is a learned behavior [19]. Nevertheless, when placed
back into the startle-paired environment the next day, morphine-
treated animals did not significantly differ from saline-treated
animals (Fig. 2f. t25= 1.23, p= 0.23).
Taken together, these results strongly suggest that changes in
SEFL are independent of changes in general anxiety or stimulus
sensitivity. Instead, they suggest that opioid treatment influences
the ability of trauma to alter aversive learning.
Chronic opioid treatment potentiates trauma-induced changes in
fear learning and not fear expression
To address whether opioid pre-exposure alters the induction or
expression of enhanced fear, we examined the impact of giving
chronic opioid treatment after the initial trauma but before the
rest of the SEFL procedure (Fig. 3). Because this was the first time a
fear memory acquired prior to morphine administration was
examined subsequent to it, this experiment allowed us to assess
whether morphine acted merely to impact fear expression, or
whether it altered fear learning. Furthermore, because the trauma
was experienced before morphine exposure, we were able to
further explore the nature of the interaction between trauma and
opioid exposure in impacting subsequent fear learning. Upon
being returned to the trauma environment after morphine
treatment, animals given morphine did not display altered fear
of the trauma environment (Fig. 3b. Effect of morphine: F1,70=
0.02, p= 0.89. Morphine × trauma interaction: F1,70= 0.04, p=
0.84). Thus, morphine exposure did not enhance the expression of
a previously acquired fear memory. Moreover, the ability of
morphine exposure to augment subsequent fear learning about a
mild stressor was no longer apparent (Fig. 3b. Effect of morphine:
F1,70= 2.87, p= 0.1. Morphine × trauma interaction: F1,70= 0.23,
p= 0.63). This suggests that the ability of morphine to augment
SEFL depends upon it influencing changes produced by trauma.
Chronic opioid pretreatment potentiates SEFL independent of
treatment frequency and bouts of acute withdrawal
The experience of acute withdrawal is frequently posited to
underlie the changes in negative affective states associated with
addiction [20, 21]. In order to assess the relative contribution of
negative affective states produced by acute withdrawal on the
Fig. 1 Chronic opioid pretreatment potentiates SEFL. a Schematic of the SEFL procedure. During the trauma, animals received 10, 1 s, 1 mA
shocks. The next day they were returned for the trauma test. Subsequently, animals received a single 2 s, 0.5 mA shock, in a novel environment
(the mild stressor). The following day they were placed back in this environment for the SEFL test. b By the end of the weeklong cessation
period when they received the trauma, morphine-treated animals’ weight was no longer different from saline-treated animals. c Throughout
the trauma and when subsequently returned to the trauma context for the trauma test, morphine- and saline-treated animals did not differ. d
After being given a single shock in a novel environment, animals that underwent trauma froze more than non-trauma animals when returned
to that environment—evidence of SEFL—and morphine-treated animals showed this effect to a much greater degree. Dashed line in d
reflects average pre-shock baseline freezing on the previous day. Error bars reflect standard error of the mean. Asterisk reflects significance at
p < 0.05. n.s. not significant, bl baseline. Group sizes for b–d: n= 22–24/group
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observed enhancement in fear learning we separately manipu-
lated the frequency of opioid exposure, which alters the impact of
opioid treatment, and the frequency and magnitude of acute
withdrawal (Fig. 4).
To manipulate opioid treatment frequency, animals were given
16 saline/morphine injections, but either over 8 days (2× daily) or
16 days (1× daily; Fig. 4a). Demonstrating that this manipulation
altered the impact of opioid exposure, mice treated with
Fig. 2 Chronic opioid pretreatment does not alter shock sensitivity or anxiety. a Experiment Schematic. A week after chronic morphine/saline
exposure, animals were tested in the EPM. The next day, shock reactivity was assessed. b Morphine-treated animals did not display altered
exploration of the open arms of the EPM. c Morphine-treated animals did not display altered shock reactivity. See Supplemental Methods for
details. Dashed line in c reflects pre-shock motion prior to the first shock, which did not differ between groups (t22= 0.1, p= 0.92).
d Experiment Schematic. A subset of animals which received morphine/saline and were fear conditioned with a single 2 s, 0.5 mA shock, were
subsequently exposed to a series of auditory startle stimuli (2 s, 115 db, white noise, each separated by 1min) in a novel environment, and
were placed back in the startle-paired environment the next day. e Morphine-treated animals did not differ with respect to baseline motion or
startle-induced increases in motion. f Morphine-treated animals did not differ with respect to baseline freezing when initially placed in the
startle-paired environment but showed increased post-startle freezing, a learned behavior. Nevertheless, when placed back into the startle-
paired environment the next day, morphine-treated animals did not significantly differ from saline-treated animals. Error bars reflect standard
error of the mean. BL baseline. For a–c, n= 12/group. For d–f, n= 13–14/group
Chronic opioid pretreatment potentiates the sensitization of fear. . .
ZT Pennington et al.
485
Neuropsychopharmacology (2020) 45:482 – 490
morphine once per day lost substantially less weight than mice
treated twice per day: by the end of morphine administration,
animals treated twice per day had lost more weight than those
treated once per day (Fig. 4b. t14= 4.28, p < 0.001), although
animals treated with morphine once per day had lost some weight
relative to saline-treated animals (Fig. 4b. t18= 3.95, p < 0.001).
However, regardless of the frequency of morphine administration,
morphine-treated animals showed a similar enhancement in SEFL
(Fig. 4c. Effect of morphine: F1,24= 12.27, p < 0.01; effect of
frequency: F1,24= 1.18, p= 0.29; morphine × frequency interac-
tion: F1,24= 0.59, p= 0.45).
To provide a more drastic manipulation of acute withdrawal, we
implanted mice with subcutaneous morphine pellets, which have
been shown to provide a continual release of morphine that drops
off slowly over 5–7 days [22, 23]. This allowed us to prevent mice
from cycling through repeated acute withdrawal. Then, in order to
experimentally mimic the repeated acute withdrawal process, half
of the animals received twice-daily injections of the opioid
antagonist naltrexone (0.25 mg/kg, i.p.) for 7 days, which
precipitates withdrawal (Fig. 4d). To confirm withdrawal behaviors
across the course of naltrexone treatment, we examined defeca-
tion and jumping behavior, two classic metrics of withdrawal [23].
As can be seen in Fig. 4e, only morphine animals injected with
naltrexone displayed increases in these behaviors (morphine ×
naltrexone interaction on defecation: F1,23= 56.03, p < 0.001;
effect of naltrexone on defecation in morphine group: F1,11=
127, p < 0.001; effect of naltrexone on defecation in placebo
group: F1,12= 0.38, p= 0.55; Only morphine-naltrexone animals
showed any jumping behavior). A week after the last naltrexone
injection, at a time in which morphine has been out of the
animals’ system for several days [23], animals underwent the SEFL
procedure. Supporting a lack of analgesic effect at this timepoint,
morphine-treated animals displayed no differences in locomotor
response to shock at the time of trauma (effect of morphine:
F1,23= 1.05, p= 0.32; morphine × naltrexone interaction: F1,23=
0.51, p= 0.48. Data not shown). Despite the enormous differences
in withdrawal behaviors, in the final SEFL test animals implanted
with morphine pellets expressed enhanced freezing relative to
animals implanted with placebo pellets, and there was no impact
of naltrexone treatment (Fig. 4f: effect of morphine: F1,23= 5.13,
p= 0.03; effect of naltrexone: F1,23= 1.56, p= 0.22; morphine ×
naltrexone interaction: F1,23= 0.05, p= 0.83). Consequently, acute
morphine withdrawal is unlikely to have produced the effects we
observed on fear learning.
Neural correlates of enhanced fear learning following opioid
exposure
Having demonstrated that chronic opioid pre-exposure is able to
alter the ability of trauma to sensitize fear learning in a
withdrawal-independent manner, we next sought to identify
functional differences in brain regions associated with anxiety and
fear learning which may support this change. A set of animals
were treated with the morphine regimen previously described and
were then then exposed to the EPM prior to collecting tissue for
immediate early gene immunohistochemistry (Fig. 5a–e). This was
done in order to examine baseline levels of neural activity that
might predate the enhanced SEFL phenotype. Here, prior
morphine exposure did not alter c-Fos protein levels in multiple
regions critical to fear learning and anxiety (basolateral amygdala,
BLA; central nucleus of the amygdala, CEA; and bed nuclei of the
stria terminalis, BNST). Although c-Fos was induced in the BLA and
CEA in response to EPM exposure (orthogonal contrasts of
experimental animals vs. homecage controls: BLA: t12= 3.61, p <
0.01; CEA: t12= 2.14, p= 0.05; BNST: F12= 1.49, p= 0.16), there
were no differences in EPM-induced c-Fos between saline- and
morphine-treated animals in these regions (BLA: t12= 0.19, p=
0.85; CEA: t12= 0.68, p= 0.57). Additionally, no differences in
GluA1 immunofluorescence were found in morphine-treated
animals within the BLA (t9= 0.16, p= 0.88).
Because the SEFL trauma increases GluA1 AMPA receptor
subunit protein levels in the BLA [11]—an endpoint of long-term
potentiation necessary for fear learning to occur [24]—we lastly
assessed BLA GluA1 protein levels in morphine-treated animals
that had undergone the SEFL procedure (Fig. 5f–h). We found that
post-learning enhancements in GluA1 expression were greater in
morphine-treated animals (Fig. 5g. t21= 2.46, p= 0.02). Moreover,
Fig. 3 Chronic opioid pretreatment potentiates trauma-induced changes in fear learning and not fear expression. a Experiment schematic.
Chronic morphine and a week of drug cessation were given in-between the trauma and the rest of the SEFL procedure. b Morphine-treated
animals do not display altered fear of the trauma context when placed back into it, demonstrating that morphine administration does not
increase fear expression. c Morphine-treated animals display a trend toward heightened fear in the SEFL test, but this did not reach
significance. Dashed line in c reflects average pre-shock baseline freezing on the previous day. Error bars reflect standard error of the mean.
N= 18–19/group
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GluA1 expression was predictive of the enhancement in SEFL
(Fig. 5h). Multiple regression analysis jointly predicting SEFL test
freezing from GluA1 protein levels and morphine treatment (y=
B0+ B1×GluA1+ B2×morphine) revealed that GluA1 was a
significant predictor of SEFL test freezing (Fig. 1f. B1= 6.36, t=
2.56, p= 0.02), above and beyond the influence of morphine
(B2= 9.67, t= 1.99, p= 0.06). Thus, while morphine alone did not
change GluA1 protein levels, it potentiated the increase in GluA1
triggered by stress, supporting the idea that plasticity within fear
learning-circuitry is enhanced in morphine-treated animals.
Fig. 4 Chronic opioid pretreatment potentiates SEFL independent of acute withdrawal. a To manipulate opioid treatment frequency, animals
were given 16 saline/morphine injections, either over 8 (2× daily) or 16 days (1× daily), and a week later were run through the SEFL procedure.
b Twice-daily morphine produces more drastic weight loss than once-daily morphine. c Irrespective of injection frequency, morphine
treatment potentiated SEFL. d To manipulate opioid withdrawal, animals were implanted with placebo/morphine pellets, providing a
sustained release of morphine, and were then given twice-daily injections of saline/naltrexone twice/day for 7 days to precipitate withdrawal.
A week after the last injection, at a time when morphine is fully out of their system, all animals were run through the SEFL procedure.
e Morphine animals treated with naltrexone display robust withdrawal. f Irrespective of the amount of withdrawal, animals implanted with
morphine pellets display heightened SEFL. Dashed line in c/f reflects average pre-shock baseline freezing of all animals on the previous day.
Error bars reflect standard error of the mean. Asterisk reflects significance at p < 0.05. Asterisks next to legend denote main effect of morphine
treatment. NTX naltrexone. For b, c: n= 6–8/group. For e, f: n= 6–7/group
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DISCUSSION
Here we demonstrate a dramatic ability of chronic opioid
regimens to subsequently potentiate SEFL, a finding that may
provide insight into the comorbidity between PTSD and opioid
dependence. Given that this potentiation lasts for some time
beyond discontinuation of drug exposure, it is possible that
sensitization of fear learning predisposes individuals who have
used opioids—either as prescribed or illicitly—to develop PTSD.
It is important to emphasize that the observed enhancement in
fear appears to be a consequence of a facilitation of the biological
processes that give rise to the formation of fear memories, as
opposed to some other cognitive or physiological process that
influences fear expression. First, great care was taken to ensure
that the differences observed in opioid-treated animals were not
the consequence of increased sensitivity to shock, the aversive
stimulus used in the bulk of these experiments. Across a wide
range of shock amplitudes, we were unable to detect differences
in shock-induced motor responses between saline- and morphine-
treated animals, despite being within the dynamic range to detect
such differences. Although it could be argued that the motor
Fig. 5 Biological correlates of enhanced fear learning following opioid exposure. a–e Post-EPM induced c-Fos and GluA1 across anxiety
circuitry. a Experiment Schematic. In order to examine basal levels of activity across fear and anxiety circuitry, morphine/saline-treated animals
were tested in the EPM after a week of cessation and tissue was taken for c-Fos and GluA1 immunohistochemistry. Homecage controls (HC)
were treated with saline/morphine but were not placed in the EPM. No differences in induced c-Fos protein were observed in the BLA (b), CEA
(c), or BNST (d) between morphine- and saline-treated mice. See Fig. S2 for fos images. e Additionally, no differences in GluA1
immunofluorescence were found in morphine-treated mice at this timepoint. f–e Post-learning changes in BLA GluA1 in morphine-treated
mice. f Experiment schematic. In a set of animals treated with saline/morphine and run through the SEFL procedure, tissue was taken after the
final SEFL test and GluA1 immunohistochemistry was performed in the BLA. g Morphine-treated animals displayed greater GluA1
immunofluorescence in the BLA after SEFL than saline-treated animals and h regression analysis predicting SEFL test freezing from GluA1
levels and morphine treatment showed that levels of GluA1 were predictive of SEFL, over and above the effect of morphine treatment.
Regression equation and coefficients are adjacent to scatterplot. i Exemplary images of GluA1 expression in the BLA of saline and morphine
animals. Error bars reflect standard error of the mean. Group Sizes for a–e: homecage: n= 4 (two saline, two morphine); saline: n= 6;
morphine: n= 6. For GluA1, only non-Homecage animals were assessed. Group sizes for f–i: 9–14/group
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responses measured do not parallel the internal subjective
response to shock (a problem inherent in most animal pain
assays because they rely upon a behavioral response), this is
unlikely to be the case. After repeated trials, maximal freezing to a
stimulus paired with a shock is directly related to shock magnitude
[25, 26]. However, we found no differences in freezing between
morphine- and saline-treated animals at the trauma test, when
freezing is at asymptotic levels, further suggesting that the
perceived magnitude or aversiveness of the stimulus was not
different. Moreover, we found increased freezing to auditory
startle stimuli in morphine-treated animals, suggesting that
enhancements in aversive learning were not exclusive to painful
shocks.
The increase in fear learning observed is also unlikely to be a
consequence of a general state of increased anxiety following
opioid treatment. Morphine-treated animals did not display
altered fear generalization following trauma when they were
placed in a novel context prior to receiving the mild stressor, nor
did they differ in their exploration of the open arms of an EPM at a
time in which they show heightened fear learning. This suggests
that they were not more anxious. Moreover, when animals
experienced a trauma prior to morphine exposure, animals did
not differ with respect to freezing when subsequently returned to
the context of the traumatic event, providing evidence that
expression of a previously learned fear response is unaffected.
Consequently, morphine appears to have altered the ability with
which negative experiences affect future behavior—that is to say,
learning.
Chronic opioid exposure prior to trauma, but not after trauma,
facilitated SEFL. This finding suggests that the biological
changes induced by chronic opioid treatment must be
present at the time of trauma for fear learning to be enhanced
by morphine. In other words, chronic opioid exposure alters the
induction of SEFL. There are several points worth mentioning
about this finding. First, in the experiment where morphine was
administered after trauma, saline-treated animals appeared to
show a greater SEFL effect than when saline/morphine
was administered before trauma. This is potentially due to the
longer delay between the traumatic experience and the mild
stressor in this experiment. Although we have not formally
tested this possibility, perhaps SEFL is subject to incubation.
Nevertheless, because saline-treated animals still froze less
than 30% in the final SEFL test, it is hard to argue that a ceiling
effect prevented our ability to detect an increase in morphine-
treated animals. It is also noteworthy that when morphine was
given following trauma there was a trend for morphine to
augment fear in the final SEFL test (p= 0.1), although this
took the form of a main effect and not an interaction with
traumatic experience. In combination with the finding that
morphine potentiated freezing to startle stimuli, despite these
animals only having experienced a mild stressor previously, it
appears that the ability of opioid exposure to augment
fear learning is not entirely dependent upon traumatic
experience. However, it is substantially clearer when the two
are combined.
Opioid pre-exposure, and not one of its major sequelae, acute
withdrawal, appears to be directly responsible for this change in
stress reactivity. Repeated and robust withdrawal did not augment
the ability of opioid pretreatment to enhance SEFL. Moreover,
reducing the frequency of morphine administration to weaken its
impact similarly did not mitigate enhancements in SEFL. These
findings indicate that the enhancement in SEFL by morphine is
not a consequence of the stress of repeated morphine withdrawal,
but instead might be a consequence of alterations in circuitry
associated with morphine pre-exposure. It is worth mentioning
that despite manipulating withdrawal, these experiments did not
directly compare the amount of dependence induced by various
morphine procedures. It is conceivable that the critical variable is
whether or not dependence is produced, irrespective of
observable withdrawal symptoms. For instance, it has previously
been reported that long access to heroin self-administration
produces greater levels of dependence, anxiety, and drug seeking
than short access heroin self-administration in rodents [27, 28],
and in humans it has been shown that prior opioid use is
associated with the development of PTSD and treatment-resistant
depression [29–31]. Whether these changes are a consequence of
dependence, acute withdrawal, cumulative opioid exposure, or
comorbid pathology has not been disentangled. Regardless,
because dependence is often unavoidable in the medicinal use
of opioids, even when withdrawal can be minimized, the finding
that changing the amount of withdrawal experienced does not
change the observed potentiation of fear learning is of clear
clinical interest.
In conjunction with the finding that morphine exposure
enhances SEFL, an altered marker of synaptic plasticity within
the BLA was also found in morphine-treated animals. Chronic
morphine treatment resulted in post-learning, but not pre-
learning, increases in the GluA1 subunit of the AMPA receptor
within the BLA. Moreover, the degree of GluA1 increase was
found to be highly predictive of the amount of SEFL displayed.
Importantly, the BLA is thought to be the site of synaptic
plasticity supporting associative fear learning [32, 33], produc-
tion and insertion of GluA1-containing AMPA receptors are a
correlate of long-term potentiation (LTP) [34, 35], and blocking
incorporation of these receptors into the membrane within the
amygdala has been shown to block associative fear learning
[24]. Thus, in addition to the behavioral indicators that fear
learning is enhanced, we also find that a component of the
molecular cascade that supports fear learning was similarly
enhanced. Unfortunately, it is currently not possible to
directly test the causal contribution of this GluA1 upregulation
to the enhancement in SEFL seen following opioid exposure.
This is because any manipulation that would reduce the GluA1
upregulation in morphine-treated animals is also anticipated
to produce drastic impairments in fear learning in morphine-
naïve mice, as has been previously shown [24]. As such, it would
be difficult to conclude anything specific about a morphine-
induced enhancement from this sort of manipulation. Therefore,
here we simply take enhanced GluA1 expression in the BLA as
corroborative evidence that BLA-dependent learning is changed
by morphine. Future work hopes to isolate the molecular
cascade leading to this change. For instance, given that
opioid receptors are located throughout the fear circuitry
[36, 37], how might chronic opioid treatment act on specific
receptors to alter the functional dynamics of this circuitry? Mu
opioid receptors are richly expressed within the BLA, although
given a general paucity of mu mRNA within the BLA, these
receptors are likely to be located on presynaptic afferents
[36, 37]. Perhaps chronic opioid exposure and subsequent
receptor desensitization/internalization opposes the inhibitory
influence these receptors normally have on excitatory inputs to
the BLA, which could in turn facilitate fear. Alternatively, kappa
opioid receptors are also expressed within the amygdala and
have been shown to regulate anxiety [38, 39]. It is conceivable
that chronic activation of kappa receptors potentiates fear
learning. By understanding the receptor signaling pathways
leading to this change, it may be possible to mitigate the impact
of opioids on fear.
In closing, these results provide compelling evidence that
chronic opioid exposure is able to robustly enhance the ability of
trauma to sensitize fear learning. Given the striking comorbidity
between PTSD and opioid dependence, as well as the growing
prevalence of opioid use and dependence in our society, these
findings provide a potential mechanistic link between these
conditions and further call into question the safety of both licit
and illicit opioid use.
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